Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label rilzabrutinib study in warm autoimmune hemolytic anemia
2021-001671-16Phase 2Active
- Sponsor
- Sanofi
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilzabrutinib in warm autoimmune hemolytic anemia (wAIHA), sponsored by Sanofi. Primary endpoint: Proportion of participants with overall hemoglobin response. Started Jun 2021; status: active.
02
Drugs
rilzabrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2021-001671-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001671-16.